Marshall Urist, M.D., Ph.D.

Marshall Urist, M.D., Ph.D.

Executive Vice President, Research & InvestmentsatRoyalty Pharma· In proxies 2021–2025

Pay in FY2025+5% from the year before · Royalty Pharma stock +51.5% the same year

Marshall Urist, M.D., Ph.D. was paid $1.3M in FY2025 (Dec), up 5%. Royalty Pharma stock rose 51.5% that year.

Pay$100 in the stock at the end of FY20 → $80
Pay is from the Summary Compensation Table of each Royalty Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Royalty PharmaPublic company · 5 yr
    • Executive Vice President, Research & Investments2021 – Present · 5 yrStock in role +37%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?